Patents Assigned to Baylor College of Medicine
  • Patent number: 10351824
    Abstract: The present disclosure relates to a novel process for expanding T cells, such as autologous T cells, cell populations therefrom, pharmaceutical compositions comprising the said cell populations and use of the cells and compositions for treatment, particular the treatment or prophylaxis of virus infection and/or cancer, for example in immune compromised or immune competent human patients.
    Type: Grant
    Filed: April 23, 2012
    Date of Patent: July 16, 2019
    Assignees: Cell Medica Limited, Baylor College of Medicine
    Inventors: Cliona M. Rooney, Ann M. Leen, Juan F. Vera, Minhtran V. Ngo, Rainer Ludwig Knaus
  • Patent number: 10328127
    Abstract: Embodiments of the disclosure concern methods and compositions that relate to increasing or decreasing the weight (including, for example, by increasing or decreasing the adipose mass) in individuals in need thereof. Such methods and compositions, in particular embodiments, concern providing an effective amount of the hormone asprosin to increase adipose mass in an individual with insufficient adipose mass and providing an antibody or inhibitor of asprosin in an individual with obesity or diabetes, for example, to reduce adipose mass.
    Type: Grant
    Filed: November 24, 2014
    Date of Patent: June 25, 2019
    Assignee: Baylor College of Medicine
    Inventors: Atul Chopra, David D. Moore
  • Publication number: 20190175397
    Abstract: The present disclosure concerns hyperthermic devices for treating vascular involvements related to cancer therapies, such as surgery. In specific embodiments, the device is configured to provide therapeutic heating to destroy vessel-encasing tumors while still protecting the vessel itself. In particular embodiments, the devices utilize two opposing semi-cylindrical shells that encase the vessel in need of treatment of a tumor thereon. In other devices, a flexible substrate is guided under and around the vessel and tumor thereon.
    Type: Application
    Filed: May 12, 2017
    Publication date: June 13, 2019
    Applicant: Baylor College of Medicine
    Inventors: Stuart James Corr, Matthew James Ware, Steven A. Curley, Lam Nguyen
  • Patent number: 10301647
    Abstract: The invention relates to an adenoviral-based biological delivery and expression system for use in the treatment or prevention of osteoathritis in human or mammalian joints by long-term inducible gene expression of human or mammalian interleukin-1 receptor antagonist (Il-1Ra) in synovial cells, comprising a helper-dependent adenoviral vector containing a nucleic acid sequence encoding for human or mammalian interleukin-1 receptor antagonist (Il-1Ra), left and right inverted terminal repeats (L ITR and R ITR), the adenoviral packaging signal and non-viral, non-coding stuffer nucleic acid sequences, wherein the expression of the human or mammalian interleukin-1 receptor antagonist (Il-1Ra) gene within synovial cells is regulated by an inflammation-inducible promoter.
    Type: Grant
    Filed: January 23, 2013
    Date of Patent: May 28, 2019
    Assignee: Baylor College of Medicine
    Inventors: Brendan Lee, Kilian Guse, Zhechao Ruan
  • Patent number: 10301671
    Abstract: Embodiments of the disclosure encompass methods of amplifying nucleic acid from one or more cells using MALBAC (multiple annealing and looping-based amplification cycles) primers. In particular embodiments, the nucleic acid is amplified as amplicons in a linear manner. Specific embodiments include the removal or effective destruction of nonlinearly produced amplicons.
    Type: Grant
    Filed: May 5, 2015
    Date of Patent: May 28, 2019
    Assignee: Baylor College of Medicine
    Inventors: Chenghang Zong, Michael Gundry, Kuanwei Sheng
  • Patent number: 10286065
    Abstract: Embodiments are directed to compositions and methods for treating viral infections.
    Type: Grant
    Filed: September 21, 2015
    Date of Patent: May 14, 2019
    Assignees: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM, BAYLOR COLLEGE OF MEDICINE, PULMOTECT, INC.
    Inventors: Burton Dickey, Scott Evans, Brian Gilbert, Diane Markesich, Brenton Scott, Michael Tuvim
  • Patent number: 10279009
    Abstract: Embodiments of the invention employ methods and compositions for enhancing potency of immune cells that express one or more therapeutic proteins. In certain cases, the methods modulate expression of a CAR transgene in an immune cell, such as a T cell. Specific embodiments employ the exposure of cells and/or individuals to be treated with the cells with an effective amount of at least one agent that upregulates expression of the therapeutic protein, such as a mitogen, histone deacetylase inhibitor, and or DNA methyltransferase inhibitor.
    Type: Grant
    Filed: July 18, 2014
    Date of Patent: May 7, 2019
    Assignee: Baylor College of Medicine
    Inventors: Juan Fernando Vera Valdes, Malcolm Brenner, Usanarat Anurathapan
  • Patent number: 10280470
    Abstract: Embodiments of the invention include methods and/or compositions for analysis of samples for C. difficile infection to determine whether or not an individual is at risk for having recurrent C. difficile infection or a CDI misdiagnosis. Methods include characterization of microflora composition from the gut, wherein alterations of the microflora gut composition are indicative of recurrence of infection. Methods include analysis of nucleic acids from the gut, such as 16S rRNA as being identifying of a particular bacteria in the analysis of bacterial populations of the gut.
    Type: Grant
    Filed: January 13, 2014
    Date of Patent: May 7, 2019
    Assignee: Baylor College of Medicine
    Inventors: Tor Savidge, Emily Hollister-Branton
  • Publication number: 20190125176
    Abstract: One aspect of the invention provides a trocar including: a central cylinder defining a central channel and having a distal end adapted and configured for insertion within a subject; one or more gas outlets located within the central cylinder proximate to the distal end of the trocar; and one or more liquid outlets located within the central cylinder on a proximal side of the one or more gas outlets. The one or more liquid outlets are adapted and configured to dispense a liquid when an endoscope is withdrawn from a fully extended position within the central channel of the trocar to a position proximate to the one or more liquid outlets. Distal advancement of the endoscope to a position adjacent to the one or more gas outlets removes liquid from a distal end of the endoscope.
    Type: Application
    Filed: April 13, 2017
    Publication date: May 2, 2019
    Applicants: Baylor College of Medicine, Texas Heart Institute
    Inventors: Bryan M. Burt, Mahmood Khan, William Cohn
  • Patent number: 10265315
    Abstract: Small molecule regulators of steroid receptor coactivator (SRC) family proteins are provided, as well as methods for their use in treating or preventing SRC-related diseases. The SRC-related diseases can include cancer, metabolic disorders, human immunodeficiency virus, neurodegenerative disorders, and/or inflammatory diseases. Also provided are methods for regulating SRC family proteins in a cell.
    Type: Grant
    Filed: April 6, 2017
    Date of Patent: April 23, 2019
    Assignee: BAYLOR COLLEGE OF MEDICINE
    Inventors: Bert W. O'Malley, David Michael Lonard, Jin Wang, Jianming Xu, Jianwei Chen
  • Patent number: 10260100
    Abstract: The present invention relates to neuropathy, in particular to mutations in the FIG4 gene. The present invention also provides assays for the detection of variant FIG4 alleles, and assays for detecting FIG4 polymorphisms and mutations associated with disease states.
    Type: Grant
    Filed: May 12, 2016
    Date of Patent: April 16, 2019
    Assignees: THE REGENTS OF THE UNIVERSITY OF MICHIGAN, BAYLOR COLLEGE OF MEDICINE
    Inventors: Miriam Meisler, James R. Lupski, Clement Chow
  • Publication number: 20190105470
    Abstract: One aspect of the invention provides a sheath including: a cylinder defining a central passage; a balloon located along an external surface of a distal end of the cylinder, the balloon lying substantially flush with or recessed from the external surface when deflated, but capable of projecting beyond the external surface when inflated; and an inflation port located at a proximal end of the cylinder, the inflation port in fluid communication with the balloon. Another aspect of the invention provides a kit including: a sheath as described herein and instructions for use.
    Type: Application
    Filed: April 6, 2017
    Publication date: April 11, 2019
    Applicant: Baylor College of Medicine
    Inventors: Naveen Yadav, Arun Rai, Christopher Graziano, Samit Soni, Richard Link
  • Patent number: 10251778
    Abstract: A therapeutics delivery system, and methods of making and using same, are disclosed for environments that rapidly clear any injected therapeutics, such as a patient's eye. The therapeutics delivery system releases the drug in a therapeutically effective concentration for a desired duration of time with a predefined drug kinetics. In one embodiment, the embodiments of the present disclosure release a therapeutically effective concentration for a longer time period than other delivery systems, for instance from a day to a week. Certain embodiments comprise a therapeutics dispensing device comprising a biodissolvable hydrogel matrix for long term drug release that allows the device to be placed directly at the injured site, e.g., onto the surface at or near the injury, and retained there rather than through injection, whether locally or systematically.
    Type: Grant
    Filed: August 6, 2013
    Date of Patent: April 9, 2019
    Assignees: Baylor College of Medicine, REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Ghanashyam Acharya, Stephen C. Pflugfelder, Cintia S. De Paiva, Jennifer L. Simpson
  • Patent number: 10246496
    Abstract: Novel analogues of the sea anemone Stichodactyla helianthus toxin ShK, and their use as, for example, therapeutic agents for treating autoimmune diseases are disclosed. The analogues comprise a ShK toxin polypeptide and an N-terminal extension comprising an amino acid sequence according to formula (I): wherein X?4 is D, E or other negatively-charged amino acid or derivative thereof, X?3 is E, I, L, S, V, W or a tryptophan derivative, X?2 is any amino acid, X?1 is any amino acid, a is absent or a first additional moiety, and b is absent or a second additional moiety.
    Type: Grant
    Filed: August 14, 2015
    Date of Patent: April 2, 2019
    Assignees: LA TROBE UNIVERSITY, MONASH UNIVERSITY, BAYLOR COLLEGE OF MEDICINE, PEPTIDES INTERNATIONAL, INC.
    Inventors: Raymond S. Norton, Shih Chieh Chang, Michael W. Pennington, Christine Beeton, Brian J. Smith
  • Patent number: 10246560
    Abstract: Embodiments of the invention concern copolymers and nanoparticles for use as delivery agents for one or more agents for therapy for a medical condition of humans and animals. Some of embodiments of the invention provide new reagents for biomedical research in cell culture, animal models and plants, for example. The copolymers comprise PLGA and PEI and, in some embodiments, also comprise 1-(3-aminopropyl)-4-methylpiperazine (APMP), Fc binding peptide and/or antibody. In certain embodiments, APMP-PLGA-PEI, Fc binding peptide/antibody-PLGA-PEI or Fc binding peptide/antibody-AP-MP-PLGA-PEI nanoparticles comprising one or more therapeutic agents are delivered to an individual in need thereof or used for biomedical research in cell cultures, animal models and plants.
    Type: Grant
    Filed: August 13, 2014
    Date of Patent: April 2, 2019
    Assignee: Baylor College of Medicine
    Inventors: Jian-Ming Lu, Qizhi Yao, Changyi Chen
  • Patent number: 10227656
    Abstract: Embodiments of the present disclosure concern methods and compositions for prognosis, diagnosis, and/or treatment of prostate cancer or breast cancer, for example. Certain embodiments of the disclosure concern assaying for the expression level of TDRD1. Particular embodiments concern treating an individual with a particular cancer therapy when the expression level of TDRD1 is overexpressed.
    Type: Grant
    Filed: November 7, 2014
    Date of Patent: March 12, 2019
    Assignee: Baylor College of Medicine
    Inventors: Bin He, Rainer B. Lanz, Nicholas Mitsiades, Qin Feng
  • Publication number: 20190046569
    Abstract: Embodiments of the disclosure concern methods and compositions related to cancer therapy using myeloid derived suppressor cells (MDSC) as a solo therapy or an adjunct therapy. The MDSCs are prepared by exposing bone marrow cells or blood cells to one or more compositions that induce their differentiation to MDSCs and also to TGF-?1, and in specific embodiments the exposure to TGF-?1 results in the MDSCs having anti-tumor activity and/or immune stimulatory activity.
    Type: Application
    Filed: September 14, 2016
    Publication date: February 14, 2019
    Applicant: Baylor College of Medicine
    Inventors: Andrew SIKORA, Padmini JAYARAMAN, Falguni PARIKH, Robin PARAHIR
  • Publication number: 20190000609
    Abstract: When zonular attachments of a capsule holding an implanted lens weaken after cataract surgery, a capsular clip may be utilized to secure the capsular bag to the eye wall. The capsular clip may comprise an eyelet and a flat hook. The hook may be inserted either via a small surgeon created separation between the anterior capsule leaflet and the intraocular lens or via puncturing the capsular bag in a small area, and may be placed between the capsular bag and the implanted lens to secure the capsule in the appropriate position within the eye. Suture thread may be fed through the eyelet of the capsular clip to sew the capsular clip to the eye wall, thus securing the capsular clip and the capsule in place.
    Type: Application
    Filed: December 15, 2016
    Publication date: January 3, 2019
    Applicant: Baylor College of Medicine
    Inventor: Marshall Bowes Hamill
  • Publication number: 20180360365
    Abstract: One aspect of the invention provides an autonomous continuous bladder irrigation device including: a color sensor programmed to detect a color of outflow from a catheter; an occlusion unit programmed to adjustably occlude a lumen providing irrigation to the catheter; and a controller in communication with the color sensor and the occlusion unit and programmed to control the occlusion unit to titrate irrigation flow to the catheter based on the color detected by the color sensor in order achieve a specified color of outflow from the catheter.
    Type: Application
    Filed: December 21, 2016
    Publication date: December 20, 2018
    Applicant: Baylor College of Medicine
    Inventors: Naveen Yadav, Arun Rai
  • Publication number: 20180344828
    Abstract: Recombinant adenoviruses expressing the extracellular (EC) and transmembrane (TM) domains of human HER2 (HER2ECTM) are described. The recombinant adenoviruses express a chimeric fiber protein having the adenovirus type 35 (Ad5) shaft and knob domains, which facilitates transduction of human dendritic cells by the recombinant HER2ECTM expressing adenovirus. Compositions that include dendritic cells transduced by the recombinant adenovirus and their use for treating HER-positive tumors is described.
    Type: Application
    Filed: October 31, 2016
    Publication date: December 6, 2018
    Applicants: The U.S.A., as represented by the Secretary, Department of Health and Human Services, Baylor College of Medicine
    Inventors: Lauren V. Wood, Brenda D. Roberson, Jay A. Berzofsky, John C. Morris, Jason C. Steel, Masaki Terabe, Malcolm K. Brenner